Blog

Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Open filters
Search
Tags
Author
Alison Sathe
Anders Vinther
Barbara W. Unger
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Mark Agostino
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

On-Demand Webinar | Are Laboratories Perpetuating Data Integrity Problems

No items found.
Conference Spotlight

Change Management Failures Documented in FDA Warning Letter

case studies
change control
FDA
GMP inspections
inspection trends

Redica Systems Appoints New CTO to Accelerate Technological Innovation in the Next Stage of Growth

No items found.
Trends

Instant Download | Analysis of 2021 U.S. FDA 483 GMP Observations

No items found.

Medical Device Postmarket Surveillance Requirements

No items found.

Stay Out of the Dark When it Comes to FDA Inspections

No items found.

Challenges to Integrating UDI into a QMS

No items found.

Ensure Adequate Investigations at Your CMO With a QRM Mindset

No items found.

Prevention of Cross-Contamination in the Pharma Industry

No items found.

Join Us at the 2022 PDA Annual Meeting Next Week!

No items found.

How Medical Device Manufacturers Can Integrate UDI into a QMS

No items found.

How to Address Gene Therapy Manufacturing Challenges

No items found.
Conference Spotlight

Is Your Quality System Up to Par for Your Next FDA Inspection?

No items found.
Trends

Instant Download | Yes, Warehouses Must Comply with Relevant GMPs

No items found.
Conference Spotlight

How One Pharma Firm Ensures Robust GMP CAPA Effectiveness at CMOs

No items found.

Resources for Adopting Risk-Based Thinking

No items found.

The 7 Most Common FDA 483 Observations Involving UDI

No items found.

Check Out Our Recent Free GMP Webinars

No items found.